Gemifloxacin Mesylate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317968

CAS#: 210353-53-0

Description: Gemifloxacin Mesylate is a third generation antibacterial quinolone agent that is also fluorinated. Gemifloxacin Mesylate is an oral broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. Vansen Pharma Inc. has licensed the active ingredient from LG Life Sciences of Korea. Gemifloxacin has been shown to be active against most strains of the aerobic gram-positive microorganisms- Streptococcus pneumoniae- including multi-drug resistant Streptococcus pneumoniae.


Price and Availability

Size
Price

10mg
USD 150
100mg
USD 450
1g
USD 950
10g
Ask price
Size
Price

25mg
USD 250
200mg
USD 550
2g
USD 1550
Size
Price

50mg
USD 350
500mg
USD 650
5g
Ask price

Gemifloxacin Mesylate, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 317968
Name: Gemifloxacin Mesylate
CAS#: 210353-53-0
Chemical Formula: C19H24FN5O7S
Exact Mass:
Molecular Weight: 485.49
Elemental Analysis: C, 47.01; H, 4.98; F, 3.91; N, 14.43; O, 23.07; S, 6.60


Synonym: Gemifloxacin Mesylate; Factive; CHEBI:53749; LB-20304a; SB-265805-S; gemifloxacin mesylate; LB 20304; LB-20304; LB20304; SB 265805; SB-265805;

IUPAC/Chemical Name: 7-[(4Z)-3-(aminomethyl)-4-methoxyiminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid;methanesulfonic acid

InChi Key: JIYMVSQRGZEYAX-CWUUNJJBSA-N

InChi Code: InChI=1S/C18H20FN5O4.CH4O3S/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17;1-5(2,3)4/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27);1H3,(H,2,3,4)/b22-14+;

SMILES Code: CO/N=C/1\CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F.CS(=O)(=O)O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Paim CS, Führ F, Martins MT, Gnoatto S, Bajerski L, Garcia CV, Steppe M,
Schapoval EE. Structural elucidation of gemifloxacin mesylate degradation
product. Biomed Chromatogr. 2016 Mar;30(3):459-65. doi: 10.1002/bmc.3569. Epub
2015 Sep 2. PubMed PMID: 26205148.

2: Paim CS, Verlindo de Araújo B, Volpato NM, Steppe M, Schapoval EE.
Gemifloxacin mesylate (GFM): dissolution test based on in vivo data. Drug Dev Ind
Pharm. 2015 Apr;41(4):567-72. doi: 10.3109/03639045.2014.884128. Epub 2014 Feb
12. PubMed PMID: 24517572.

3: Moussa BA, Mahrouse MA, Hassan MA, Fawzy MG. Spectrofluorimetric determination
of gemifloxacin mesylate and linezolid in pharmaceutical formulations:
Application of quinone-based fluorophores and enhanced native fluorescence. Acta
Pharm. 2014 Mar;64(1):15-28. doi: 10.2478/acph-2014-0005. PubMed PMID: 24670349.

4: Hassan SS, Hayat U, Tariq I, Ahmad I, Hayat MM, Uzair M, Ansari MT.
Spectrophotometric method for the determination of Gemifloxacin mesylate in pure
and tablet dosage form. Pak J Pharm Sci. 2014 Sep;27(5):1171-4. PubMed PMID:
25176374.

5: El-Koussi WM, Atia NN, Mahmoud AM, El-Shabouri SR. HPTLC method for direct
determination of gemifloxacin mesylate in human plasma. J Chromatogr B Analyt
Technol Biomed Life Sci. 2014 Sep 15;967:98-101. doi:
10.1016/j.jchromb.2014.07.004. Epub 2014 Jul 11. PubMed PMID: 25086419.

6: Al-Tamimi SA, Alarfaj NA, Aly FA, Al-Mohaimeed AM. Spectrofluorimetric
analysis of gemifloxacin mesylate in pharmaceutical formulations. Luminescence.
2014 Mar;29(2):127-31. doi: 10.1002/bio.2515. Epub 2013 May 17. PubMed PMID:
23681953.

7: Paim CS, Führ F, Miron DS, Steppe M, Schapoval EE. Highly selective
colorimetric method to determine gemifloxacin mesylate in the presence of a
synthetic impurity. J AOAC Int. 2014 Jan-Feb;97(1):94-8. PubMed PMID: 24672864.

8: Gouda AA, Amin AS, El-Sheikh R, Yousef AG. Spectrophotometric determination of
gemifloxacin mesylate, moxifloxacin hydrochloride, and enrofloxacin in
pharmaceutical formulations using Acid dyes. J Anal Methods Chem.
2014;2014:286379. doi: 10.1155/2014/286379. Epub 2014 Jan 22. PubMed PMID:
24587941; PubMed Central PMCID: PMC3920608.

9: Paim CS, Nogueira DR, Mitjans M, Ramos Lopez D, de Lapuente Perez J, Steppe M,
Schapoval EE, Vinardell MP. Biological safety studies of gemifloxacin mesylate
and related substances. Photochem Photobiol Sci. 2013 May;12(5):805-12. doi:
10.1039/c3pp25369d. PubMed PMID: 23361471.

10: Atia NN, Mahmoud AM, El-Shabouri SR, El-Koussi WM. Two validated
spectrofluorometric methods for determination of gemifloxacin mesylate in tablets
and human plasma. Int J Anal Chem. 2013;2013:137279. doi: 10.1155/2013/137279.
Epub 2013 May 16. PubMed PMID: 23762060; PubMed Central PMCID: PMC3670531.

11: Rao RN, Naidu ChG, Prasad KG, Narasimha R. Development and validation of a
RP-HPLC method for stability-indicating assay of gemifloxacin mesylate including
identification of related substances by LC-ESI-MS/MS, 1H and 13C NMR
spectroscopy. Biomed Chromatogr. 2011 Nov;25(11):1222-9. doi: 10.1002/bmc.1594.
Epub 2011 Mar 3. PubMed PMID: 21370250.

12: Paim CS, Führ F, Barth AB, Gonçalves CE, Nardi N, Steppe M, Schapoval EE.
Gemifloxacin mesylate (GFM) stability evaluation applying a validated bioassay
method and in vitro cytotoxic study. Talanta. 2011 Feb 15;83(5):1774-9. doi:
10.1016/j.talanta.2010.11.069. Epub 2010 Dec 4. PubMed PMID: 21238783.

13: Roy B, Das A, Bhaumik U, Sarkar AK, Bose A, Mukharjee J, Chakrabarty US, Das
AK, Pal TK. Determination of gemifloxacin in different tissues of rat after oral
dosing of gemifloxacin mesylate by LC-MS/MS and its application in drug tissue
distribution study. J Pharm Biomed Anal. 2010 Jun 5;52(2):216-26. doi:
10.1016/j.jpba.2009.12.019. Epub 2009 Dec 29. PubMed PMID: 20092976.

14: Rote AR, Pingle SP. Reverse phase-HPLC and HPTLC methods for determination of
gemifloxacin mesylate in human plasma. J Chromatogr B Analyt Technol Biomed Life
Sci. 2009 Nov 1;877(29):3719-23. doi: 10.1016/j.jchromb.2009.08.013. Epub 2009
Aug 18. PubMed PMID: 19716354.

15: Hyun MH, Han SC, Cho YJ, Jin JS, Lee W. Liquid chromatographic resolution of
gemifloxacin mesylate on a chiral stationary phase derived from crown ether.
Biomed Chromatogr. 2002 Aug;16(5):356-60. PubMed PMID: 12210509.